Last reviewed · How we verify
SP-AQ
SP-AQ is a Small molecule drug developed by London School of Hygiene and Tropical Medicine. It is currently in Phase 2 development. Also known as: Seasonal IPTc with Fansidar plus amodiaquine (Flavoquine).
SP-AQ is a small molecule used in intermittent preventive treatment for malaria, particularly falciparum, and has also been studied for its effects on anaemia during pregnancy. It is administered in combination with amodiaquine or as a standalone treatment, and has been tested in a randomized controlled trial in schools.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | SP-AQ |
|---|---|
| Also known as | Seasonal IPTc with Fansidar plus amodiaquine (Flavoquine) |
| Sponsor | London School of Hygiene and Tropical Medicine |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Perennial Malaria Chemoprevention in the Malaria Vaccine Era (PHASE4)
- MDA and Targeted Control Against Plasmodium Carriage in the Sahel (NA)
- Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi (PHASE4)
- Understanding and Maximizing the Community Impact of Antimalarial Treatment (INDIE-SMC) (NA)
- Parasite Clearance and Protection from Infection (PCPI) in Cameroon (PHASE3)
- Efficacy and Safety of Sulphadoxine-pyrimethamine and Amodiaquine in Ghanaian Pregnant Women (PHASE3)
- Evaluation of Vector and Chemoprevention-based Interventions to Reduce Malaria Burden in Urban Daaras of Touba, Senegal (PHASE4)
- Seasonal Malaria Vaccination (RTS,S/AS01) and Seasonal Malaria Chemoprevention (SP/AQ) Extension Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SP-AQ CI brief — competitive landscape report
- SP-AQ updates RSS · CI watch RSS
- London School of Hygiene and Tropical Medicine portfolio CI
Frequently asked questions about SP-AQ
What is SP-AQ?
Who makes SP-AQ?
Is SP-AQ also known as anything else?
What development phase is SP-AQ in?
Related
- Manufacturer: London School of Hygiene and Tropical Medicine — full pipeline
- Also known as: Seasonal IPTc with Fansidar plus amodiaquine (Flavoquine)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing